These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 37651686

  • 1. Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension.
    Danese S, Panaccione R, Abreu MT, Rubin DT, Ghosh S, Dignass A, Afzali A, Wolf DC, Chiorean MV, Vermeire S, Jain A, Charles L, Lawlor G, Osterman MT, Wu H, Canavan JB, Petersen A, Colombel JF, Regueiro M.
    J Crohns Colitis; 2024 Feb 26; 18(2):264-274. PubMed ID: 37651686
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
    Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G.
    J Crohns Colitis; 2021 Jul 05; 15(7):1120-1129. PubMed ID: 33438008
    [Abstract] [Full Text] [Related]

  • 3. Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
    Sands BE, D'Haens G, Panaccione R, Regueiro M, Ghosh S, Hudesman D, Ahmad HA, Mehra D, Wu H, Jain A, Petersen A, Osterman MT, Afzali A, Danese S.
    Clin Gastroenterol Hepatol; 2024 Oct 05; 22(10):2084-2095.e4. PubMed ID: 38723981
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
    Armuzzi A, Cross RK, Lichtenstein GR, Hou J, Deepak P, Regueiro M, Wolf DC, Akukwe L, Ahmad HA, Jain A, Kozinn M, Wu H, Petersen A, Charles L, Long M.
    Clin Gastroenterol Hepatol; 2024 May 05; 22(5):1067-1076.e3. PubMed ID: 38040274
    [Abstract] [Full Text] [Related]

  • 5. Ozanimod: A Review in Ulcerative Colitis.
    Paik J.
    Drugs; 2022 Aug 05; 82(12):1303-1313. PubMed ID: 35994200
    [Abstract] [Full Text] [Related]

  • 6. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S, True North Study Group.
    N Engl J Med; 2021 Sep 30; 385(14):1280-1291. PubMed ID: 34587385
    [Abstract] [Full Text] [Related]

  • 7. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center.
    Cohen NA, Choi D, Garcia N, Choi NK, Picker E, Krugliak Cleveland N, Cohen RD, Dalal SR, Pekow J, Rubin DT.
    Dig Dis Sci; 2024 Feb 30; 69(2):579-587. PubMed ID: 38087126
    [Abstract] [Full Text] [Related]

  • 8. P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
    Hudesman D, Long M, Wolf D, Hanauer S, Ghosh S, Petersen A, Pondel M, Silver M, Cross R, Feagan B.
    Am J Gastroenterol; 2021 Dec 01; 116(Suppl 1):S9. PubMed ID: 37461954
    [Abstract] [Full Text] [Related]

  • 9. P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
    Sands B, Pondel M, Silver M, Petersen A, Wolf D, Panaccione R, Loftus E, Colombel JF, Sturm A, D'Haens G.
    Am J Gastroenterol; 2021 Dec 01; 116(Suppl 1):S8. PubMed ID: 37461950
    [Abstract] [Full Text] [Related]

  • 10. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
    Choi D, Stewart AP, Bhat S.
    Ann Pharmacother; 2022 May 01; 56(5):592-599. PubMed ID: 34423657
    [Abstract] [Full Text] [Related]

  • 11. Update on ozanimod for ulcerative colitis.
    Antonelli EK, Del Sordo R, Morelli O, Villanacci V, Bassotti G.
    Drugs Today (Barc); 2022 Jul 01; 58(7):351-367. PubMed ID: 35851870
    [Abstract] [Full Text] [Related]

  • 12. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
    Feagan BG, Schreiber S, Afzali A, Rieder F, Hyams J, Kollengode K, Pearlman J, Son V, Marta C, Wolf DC, D'Haens GG.
    Contemp Clin Trials; 2022 Nov 01; 122():106958. PubMed ID: 36208720
    [Abstract] [Full Text] [Related]

  • 13. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group.
    Lancet Gastroenterol Hepatol; 2022 Feb 01; 7(2):128-140. PubMed ID: 34798039
    [Abstract] [Full Text] [Related]

  • 14. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB.
    Am J Gastroenterol; 2014 Nov 01; 109(11):1771-80. PubMed ID: 25155227
    [Abstract] [Full Text] [Related]

  • 15. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ.
    J Crohns Colitis; 2021 Jun 22; 15(6):950-959. PubMed ID: 33475734
    [Abstract] [Full Text] [Related]

  • 16. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
    Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, Abreu MT, Lee S, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Arora V, Panaccione R, Dignass A.
    Inflamm Bowel Dis; 2024 Mar 09. PubMed ID: 38459910
    [Abstract] [Full Text] [Related]

  • 17. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R.
    Lancet; 2022 Jun 04; 399(10341):2113-2128. PubMed ID: 35644166
    [Abstract] [Full Text] [Related]

  • 18. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
    Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A, TOUCHSTONE Study Group.
    N Engl J Med; 2016 May 05; 374(18):1754-62. PubMed ID: 27144850
    [Abstract] [Full Text] [Related]

  • 19. P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.
    Colombel JF, D'Haens G, Irving P, Petersen A, Chitkara D, Marta C, Chen T, Charles L, Danese S, Ghosh S.
    Am J Gastroenterol; 2021 Dec 01; 116(Suppl 1):S9. PubMed ID: 37461956
    [Abstract] [Full Text] [Related]

  • 20. Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis.
    Suzuki Y, Motoya S, Hanai H, Hibi T, Nakamura S, Lazar A, Robinson AM, Skup M, Mostafa NM, Huang B, Thakkar R, Watanabe M.
    J Gastroenterol; 2017 Sep 01; 52(9):1031-1040. PubMed ID: 28321512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.